NCT03182634
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor, Endocrine (Hormone Therapy
Key Eligibility Criteria:
Gender: Female
Age: 18 Years and older (Adult), Senior)
Location of Metastases:
Additional Notes:
Exclusions: Patients with uncontrolled central nervous system (CNS) disease- see trial for details
https://ClinicalTrials.gov/show/NCT03182634